High dose biotin has led to many people to be chomping on loads of low dose biotin pills. But dooes it work? According to this report not very well.
High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice. Couloume L, Barbin L, Leray E, Wiertlewski S, Le Page E, Kerbrat A, Ory S, Le Port D, Edan G, Laplaud DA, Michel L.Mult Scler. 2019 Dec 17:1352458519894713
BACKGROUND:A recent controlled trial suggested that high-dose biotin supplementation reverses disability progression in patients with progressive multiple sclerosis.
OBJECTIVE:To analyze the impact of high-dose biotin in routine clinical practice on disability progression at 12 months.
METHODS:Progressive multiple sclerosis patients who started high-dose biotin at Nantes or Rennes Hospital between 3 June 2015 and 15 September 2017 were included in this prospective study. Disability outcome measures, patient-reported outcome measures, relapses, magnetic resonance imaging (MRI) data, and adverse events were collected at baseline, 6, and 12 months.
RESULTS:A total of 178 patients were included. At baseline, patients were 52.0 ± 9.4 years old, mean Expanded Disability Status Scale (EDSS) score was 6.1 ± 1.3, mean disease duration was 16.9 ± 9.5 years. At 12 months, 3.8% of the patients had an improved EDSS score. Regarding the other disability scales, scores either remained stable or increased significantly. In total, 47.4% of the patients described stability, 27.6% felt an improvement, and 25% described a worsening. Four patients (2.2%) had a relapse. Of the 74 patients (41.6%) who underwent an MRI, 20 (27.0%) had new T2 lesions, 8 (10.8%) had gadolinium-enhancing lesions. Twenty-five (14%) reported adverse event.
CONCLUSION:In this study, high-dose biotin did not seem to be associated with a clear improvement in disability.